Plasticell

Executive Summary

Plasticell is a UK-based biotechnology company focused on developing novel therapies through precise manipulation of stem cells and differentiated cell types. The company leverages its award-winning combinatorial screening technology to discover and optimize advanced cell and gene therapies, as well as small-molecule drugs. Founded in 2002 and headquartered in London, Plasticell operates in the RNA & Gene Therapy and Cell & Gene Therapy sectors. While the company has not disclosed its funding or valuation, its platform holds promise for addressing key challenges in regenerative medicine and targeted therapeutics. However, given the early-stage nature of its pipeline and limited public disclosures, the investment thesis carries significant risk. Plasticell's ability to progress its preclinical programs toward clinical validation and secure partnerships or additional funding will be critical for its near-term trajectory.

Upcoming Catalysts (preview)

• TBDPreclinical data readout from lead stem cell therapy program20% success
• Q3 2026Strategic partnership or licensing deal for combinatorial screening platform35% success
• TBDSeries A/B funding round to advance pipeline40% success